What Organon does

Organon & Co. is a global pharmaceutical company headquartered in Jersey City, New Jersey, formed in 2021 as a spin-off from Merck and listed on the NYSE under ticker OGN. The company develops, in-licenses, and commercializes a portfolio of more than 70 prescription medicines and medical devices across three franchises: Women's Health (contraception, fertility, maternal health, menopause, osteoporosis — anchored by NEXPLANON, NuvaRing, FOLLISTIM AQ, Jada System, and the newly licensed MIUDELLA copper IUD), General Medicines/Established Brands (cardiovascular, dermatology, neurology, autoimmune, respiratory — including COZAAR, VYTORIN, FOSAMAX, SINGULAIR, MAXALT, and the acquired VTAMA), and Biosimilars (HADLIMA, ONTRUZANT, RENFLEXIS, TOFIDENCE, PYZCHIVA, POHERDY, BILDYOS/BILPREVDA).

The company earns revenue primarily through branded pharmaceutical product sales ($6.2 billion in FY2025), with biosimilars contributing $691M (~11%) and growing at ~13% CAGR over five years. The business model is asset-light in product development — Organon leans heavily on in-licensing (MIUDELLA from Sebela, PYZCHIVA from Samsung Bioepis, POHERDY from Shanghai Henlius Biotech, TOFIDENCE from Bio-Thera) and selective M&A (Alydia Health $240M in 2021; Dermavant Sciences up to $1.2B in 2024; Forendo Pharma announced in 2021) — combined with a global commercial footprint reaching 140+ markets via country-specific sales teams, manufacturing/production centres in six countries (UK, Netherlands, Belgium, Indonesia, Brazil, Mexico), the Organon Pro physician portal, and patient access/assistance programs. Notable proprietary technology includes the SLIMSERT 3.7mm insertion system for MIUDELLA and multiple first-mover regulatory approvals (first US tocilizumab biosimilar, first EU pertuzumab biosimilar, first US hormone-free copper IUD in 40+ years). Distribution flows through standard pharmaceutical channels (wholesalers, GPOs, PBMs) without disclosed list pricing. The company is the subject of a definitive $11.75 billion all-cash acquisition agreement with Sun Pharmaceutical Industries announced April 27, 2026 ($14.00/share, ~24% premium), expected to close in early 2027.

Name

Organon

Legal name

Organon & Co.

Website

https://organon.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Organon is a global pharmaceutical company that develops and commercializes 70+ medicines and medical devices across women's health, biosimilars, and established brands, serving patients and prescribers in 140+ markets worldwide.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Biologics & Biosimilars Distributors (HLAIAJAH)

Keywords

• Women's health pharmaceuticals
• Biosimilar medicines
• Contraceptive products
• Postpartum hemorrhage devices
• Established brand drugs

Headquarters

HQ city

Jersey City

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Branded pharmaceutical product sales: Sale of Organon's portfolio of 70+ branded medicines across women's health (contraception, fertility, maternal health, menopause, osteoporosis) and general medicines (cardiovascular, dermatology, neurology, autoimmune, respiratory), generating $6.2 billion in revenue for the year ended December 2025.
2. Biosimilars product sales: Biosimilars franchise including HADLIMA (adalimumab), ONTRUZANT (trastuzumab), RENFLEXIS (infliximab), TOFIDENCE (tocilizumab), PYZCHIVA (ustekinumab), POHERDY (pertuzumab), BILDYOS/BILPREVDA (denosumab); biosimilar revenue reached $691 million in 2025 (~11% of total revenue) growing at ~13% CAGR over five years.
3. Medical device and contraceptive hardware sales: Sales of medical devices including the Jada System (postpartum hemorrhage) and the MIUDELLA hormone-free copper IUD (acquired via licensing agreement with Sebela Pharmaceuticals, expected commercial launch in late 2026).
4. Biosimilar licensing royalties and commercialization rights: Royalty and commercialization revenue from biosimilar partnerships, including the 2022 license and supply agreement with Shanghai Henlius Biotech granting Organon exclusive global commercialization rights (ex-China) to POHERDY (pertuzumab biosimilar), generating EU approval and US/EU market access.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels9 records

Core offering

Organon develops, manufactures, and commercializes a portfolio of more than 70 prescription medicines and medical devices focused on women's health (contraception, fertility, maternal health, menopause, osteoporosis), general medicines (cardiovascular, dermatology, neurology, autoimmune, respiratory), and biosimilars. The company distributes its branded products across 140+ markets worldwide through country-specific sales forces, manufacturing facilities, and in-licensing partnerships with developers such as Samsung Bioepis, Shanghai Henlius Biotech, Sebela Pharmaceuticals, and Bio-Thera Solutions.

Product overview

Organon's offering is a portfolio-plus-franchise architecture rather than a single unified software product: the company markets more than 70 prescription medicines and medical devices organized across three core franchises — Women's Health (e.g., NEXPLANON, NuvaRing, XACIATO, MIUDELLA, FOLLISTIM AQ, Pregnyl, Ganirelix, Jada System), Established Brands (e.g., COZAAR, VYTORIN, FOSAMAX, SINGULAIR, MAXALT, CLARINEX, PROPECIA, REMERON, SINEMET, DIPROLENE, CELESTONE SOLUSPAN), and Biosimilars (e.g., HADLIMA, ONTRUZANT, RENFLEXIS, BILDYOS, BILPREVDA, TOFIDENCE, PYZCHIVA, POHERDY) — distributed in over 140 markets worldwide. The portfolio is augmented by acquired brands (e.g., VTAMA from Dermavant), licensed assets (e.g., MIUDELLA from Sebela, PYZCHIVA and POHERDY from Samsung Bioepis and Shanghai Henlius Biotech respectively), and consumer-facing support programs (Organon Access Program, Patient Assistance Program). Together these franchises form Organon's healthcare business, organized around its mission to improve the health of women through every life stage while also serving broader general medicine needs through cardiovascular, neurology, respiratory, dermatology, autoimmune, and bone health therapies.

Differentiator

Problem solved

Functional benefit

Brands

• NEXPLANON: Contraceptive subdermal implant (etonogestrel).
• NuvaRing
• VTAMA
• HADLIMA
• ONTRUZANT
• RENFLEXIS
• TOFIDENCE
• ASMANEX
• DULERA
• SINGULAIR
• XACIATO
• FOLLISTIM AQ
• COZAAR
• ZETIA
• VYTORIN
• FOSAMAX
• PROSCAR
• PROPECIA
• REMERON
• MAXALT
• SINEMET
• CLARINEX
• DIPROLENE
• CELESTONE SOLUSPAN
• MIUDELLA
• PYZCHIVA
• POHERDY
• TOFIDENCE
• BILDYOS
• BILPREVDA

Products and services

• NEXPLANON Radiopaque etonogestrel subdermal implant for long-acting reversible contraception; for women seeking long-term contraception prescribed by trained healthcare providers.
• NuvaRing Combined hormonal contraceptive vaginal ring containing etonogestrel and ethinyl estradiol, released over a three-week period; for women prescribed hormonal contraception.
• XACIATO Clindamycin phosphate vaginal gel for the treatment of bacterial vaginosis in adult women; for women prescribed treatment for bacterial vaginosis.
• MIUDELLA Hormone-free copper intrauterine device (IUD) with SLIMSERT technology (3.7mm insertion tube), offering 99% pregnancy prevention effectiveness for up to three years; first hormone-free copper IUD introduced in the US in over 40 years.
• Jada System Medical device designed to control postpartum hemorrhage; acquired through the Alydia Health acquisition in March 2021 for $240 million; received FDA clearance for updated kit in October 2021 with US release January 2022; was divested with an $81 million gain recognized in Q1 2026.
• TOFIDENCE (tocilizumab-bavi) First approved tocilizumab biosimilar referencing ACTEMRA in the US, with expanded FDA indications including CAR T cell-induced cytokine release syndrome and hospitalized COVID-19; Organon acquired US regulatory and commercial rights in 2025 while Bio-Thera Solutions retains manufacturing.
• HADLIMA (adalimumab-bwwd) Adalimumab biosimilar injection for subcutaneous use; subject of ISPOR 2026 research on U.S. Veterans Affairs usage.
• ONTRUZANT (trastuzumab-dttb) Trastuzumab biosimilar for intravenous use in HER2-positive breast cancer; subject of ISPOR 2026 POHERDY research.
• RENFLEXIS (infliximab-abda) Infliximab biosimilar for intravenous use, an anti-inflammatory treatment for autoimmune conditions.
• BILDYOS / BILPREVDA (denosumab-nxxp) Denosumab biosimilar injection for subcutaneous use, available under two brand names in different markets.
• POHERDY (pertuzumab biosimilar) Pertuzumab biosimilar co-developed with Shanghai Henlius Biotech, first and only approved biosimilar to PERJETA in Europe for HER2-positive breast cancer; Organon holds exclusive global commercialization rights excluding China under a 2022 license and supply agreement.
• PYZCHIVA (ustekinumab biosimilar) Ustekinumab biosimilar referencing STELARA for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; Organon holds exclusive commercial rights in Canada while Samsung Bioepis retains development, manufacturing, and regulatory responsibilities.
• VTAMA (tapinarof) Cream 1% Tapinarof cream 1%, a non-steroidal topical aryl hydrocarbon receptor agonist for plaque psoriasis, with Phase 3 development underway for atopic dermatitis and pediatric eczema; acquired via the Dermavant Sciences acquisition.
• ASMANEX HFA / TWISTHALER Mometasone furoate inhalation aerosol (HFA) and inhalation powder (Twisthaler) for oral inhalation use in asthma management.
• DULERA Mometasone furoate and formoterol fumarate dihydrate inhalation aerosol for oral inhalation use in asthma.
• SINGULAIR Montelukast sodium available as chewable tablets, oral granules, and tablets for asthma and allergic rhinitis management.
• COZAAR / HYZAAR Losartan potassium tablets (Cozaar) and losartan potassium with hydrochlorothiazide tablets (Hyzaar) for hypertension management.
• VYTORIN / ZETIA / ZOCOR Cholesterol-lowering medications including ezetimibe and simvastatin (Vytorin), ezetimibe (Zetia), and simvastatin (Zocor).
• FOSAMAX / FOSAMAX PLUS D Alendronate sodium tablets (Fosamax) and alendronate sodium with cholecalciferol tablets (Fosamax Plus D) for osteoporosis treatment and prevention.
• MAXALT / MAXALT-MLT Rizatriptan benzoate tablets (Maxalt) and orally disintegrating tablets (Maxalt-MLT) for acute migraine treatment.
• CLARINEX / CLARINEX-D 12 HOUR Desloratadine tablets and oral solution (Clarinex) and desloratadine with pseudoephedrine sulfate extended release tablets (Clarinex-D 12 Hour) for allergic rhinitis.
• PROPECIA / PROSCAR Finasteride 1mg tablets (Propecia) for male pattern hair loss and finasteride 5mg tablets (Proscar) for benign prostatic hyperplasia.
• REMERON / REMERONSolTab Mirtazapine tablets and orally disintegrating tablets for the treatment of major depressive disorder.
• SINEMET Carbidopa and levodopa tablets for the treatment of Parkinson's disease and parkinsonian syndromes.
• DIPROLENE Augmented betamethasone dipropionate ointment for topical use in corticosteroid-responsive dermatoses.
• CELESTONE SOLUSPAN Betamethasone sodium phosphate and betamethasone acetate injectable suspension for anti-inflammatory and immunosuppressive therapy.
• FOLLISTIM AQ Cartridge Follitropin beta injection for subcutaneous use in controlled ovarian stimulation as part of fertility treatment.
• Ganirelix Acetate Injection Ganirelix acetate injection used in assisted reproductive technology for the prevention of premature luteinizing hormone surges.
• Pregnyl Chorionic gonadotropin for injection used in fertility treatment protocols.

Quantifiable outcome

• Portfolio reaches 140+ markets globally with 70+ medicines
• +4 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• Sebela PharmaceuticalsflagshipOEM/ Whitelabel/ Licensing Partner · 22 June 2026Organon completed a global licensing agreement with Sebela Pharmaceuticals for exclusive rights to MIUDELLA, a hormone-free copper IUD FDA-approved on February 24, 2025 as the first hormone-free copper IUD in the US in over 40 years. MIUDELLA offers 99% pregnancy prevention effectiveness for up to three years using proprietary SLIMSERT technology (3.7mm insertion tube) and will launch commercially in late 2026 via a REMS program in the US.
• Samsung BioepiscoreChannel Partner/ Reseller/ Distributor · 18 June 2026Samsung Bioepis and Organon expanded their existing development and commercialization agreement, granting Organon exclusive commercial rights in Canada for PYZCHIVA (ustekinumab biosimilar referencing STELARA) — a treatment for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis expected to launch in 2026. The expanded agreement raises the collaborative biosimilar portfolio in Canada from five to six products across immunology, oncology, and dermatology.
• Hanmi PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 21 May 2026Hanmi Pharmaceutical signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Hanmi supplies finished products; Organon handles marketing, distribution, and sales, with phased regulatory approvals and product launches planned.
• Sun Pharmaceutical Industries LimitedflagshipStrategic or Co-development Partner · 27 April 2026Sun Pharmaceutical Industries entered a definitive agreement on April 27, 2026 to acquire Organon in an all-cash transaction valued at approximately $11.75 billion enterprise value ($14.00 per share, ~24% premium). The deal is expected to close in early 2027 subject to regulatory and shareholder approvals, creating a combined entity with $12.4 billion in revenue across 150+ countries and positioning Sun Pharma among the world's Top 25 pharmaceutical companies. Funding includes $2–2.5 billion in cash plus committed bank financing from Citigroup, JPMorgan Chase, and MUFG.
• Bio-Thera SolutionscoreStrategic or Co-development Partner · 1 January 2025Bio-Thera Solutions retains manufacturing rights for TOFIDENCE (tocilizumab-bavi), the first approved tocilizumab biosimilar in the US launched May 2024. Organon acquired US regulatory and commercial rights in 2025, with the FDA approving expanded indications in June 2026 for cytokine release syndrome (CRS) and pediatric COVID-19.
• Dermavant Sciences (acquired from Roivant Sciences)flagshipStrategic or Co-development Partner · 18 September 2024Organon acquired Dermavant Sciences Ltd. on October 28, 2024 for up to approximately $1.2 billion (including $175M upfront, $75M FDA approval milestone, and up to $950M in tiered sales-based milestones), assuming ~$286M in liabilities. Dermavant brings VTAMA (tapinarof) cream, a treatment for psoriasis and atopic dermatitis, plus ongoing Phase 3 pediatric studies for tapinarof cream in ages 3 to 23 months.
• Shanghai Henlius BiotechcoreStrategic or Co-development Partner · 1 January 2022Under a 2022 license and supply agreement, Organon holds exclusive global commercialization rights (excluding China) to POHERDY (pertuzumab), a biosimilar co-developed with Shanghai Henlius Biotech. POHERDY received European Commission marketing authorization in April 2026, becoming the first and only approved biosimilar to PERJETA in Europe for all HER2-positive breast cancer indications.
• Forendo Pharma (acquisition announced)coreStrategic or Co-development Partner · 12 November 2021Organon announced plans to acquire drug development company Forendo Pharma; transaction size and timeline were not disclosed in the source.
• Alydia Health (acquired)flagshipStrategic or Co-development Partner · 1 March 2021Organon completed its acquisition of Alydia Health in March 2021 for $240 million, adding the Jada System (postpartum hemorrhage medical device) to Organon's maternal health portfolio. FDA clearance for an updated Jada System kit configuration was received in October 2021 with US release planned for January 2022.

Scale indicators10 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Bayer (Pharmaceuticals): Bayer operates a global women's health franchise (contraception including Mirena IUD, menopause, HRT) directly overlapping Organon's core reproductive health portfolio, alongside broader pharma and consumer health. It is the most direct comparator given the IUD and contraceptive franchise overlap.
• Pfizer: Pfizer operates overlapping franchises in biosimilars (via its Hospira heritage and partnerships), women's health, and established primary-care brands across cardiovascular and respiratory categories where Organon competes. It is a broad incumbent with adjacent portfolio overlap.
• Merck KGaA: Merck KGaA operates a global healthcare franchise including fertility treatments (Gonal-f, Cetrotide) directly competing with Organon's FOLLISTIM, Ganirelix, and Pregnyl, alongside a biosimilars business that overlaps Organon's franchise.
• Amgen: Amgen is a major biotech with multiple franchises targeted by Organon's biosimilar portfolio (AMJEVITA adalimumab, KANJINTI trastuzumab, etc.). It is a reference product originator whose biologics Organon's biosimilars compete against.

Direct peers

• Sandoz Group: Sandoz, spun off from Novartis in 2023, is a global biosimilars and generics leader that competes directly with Organon's biosimilar franchise (HADLIMA, RENFLEXIS, ONTRUZANT, TOFIDENCE, PYZCHIVA, BILDYOS/BILPREVDA) and shares the same in-licensing/commercialization model.
• Teva Pharmaceutical Industries: Teva is a global biosimilars and specialty pharma player with overlapping biosimilar assets (e.g., trastuzumab, denosumab) competing head-to-head with Organon, and shares the model of combining established brands with biosimilars and women's health products.
• Theramex: Theramex is a global specialty pharma focused exclusively on women's health (contraception, fertility, menopause), directly competing with Organon's reproductive and menopause portfolio. It is a focused women's health specialist comparable in scale and product overlap.
• Viatris: Viatris (formed via Mylan-Upjohn combination) operates a global established brands and biosimilars business with women's health and biosimilar assets that overlap Organon's portfolio. It shares the in-licensing/commercialization model and global distribution footprint.

Emerging players

• Biocon Biologics: Biocon Biologics is a leading global biosimilars developer and commercializer that competes with Organon's biosimilars franchise (trastuzumab, insulin, adalimumab, denosumab). It is an emerging pure-play biosimilar peer with significant pipeline overlap.

Regional players

• Aspen Pharmacare: Aspen Pharmacare is a South Africa-based specialty and women's health pharma with established brands across contraception, hormone replacement, and biosimilars, competing with Organon in emerging markets and overlapping in women's health categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/OrganonLLC
• YouTubeyoutube.com/channel/UCFXZcWljXuEhDkMCmZZ4Yzw
• Facebookfacebook.com/OrganonLLC
• LinkedInlinkedin.com/company/organon
• Instagraminstagram.com/organonllc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organon